This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
It’s time to dust off the key to the padlock which has, since the run-up to the first phase of the uncleared margin rules in September 2016, been gladly safeguarding the changes required to your margin and collateral management processes and systems.
2022 drivers and headwinds Choppy access to capitalmarkets and financing to fund ongoing operations Many life sciences companies faced challenges raising money in the capitalmarkets in 2022. Let’s dig in.
For institutional investors, therefore, private equity can offer exposure to fast-growing, high-potential, mid-sized private companies at a comparatively earlier stage of their growth trajectory than is available through the capitalmarkets. What is private equity and how does it work?
According to Cornerstone Research , the number of M&A class action filings increased from 34 in 2015 to 85 in 2016, 198 in 2017, and 182 in 2018. This trend continued in the first half of 2019, but at a slightly slower pace (72 filings in 1H19 compared to 91 in 1H18 and 91 in 2H18).
19 treatments from Pfizer, Merck and potentially others hitting the market soon , we expect Big Pharma to continue to parlay this cash flow into growth in other areas of strategic focus. A healthy 90 biopharma M&A transactions were announced in 2021 (compared to 69 in 2020 and 70 in 2019, the most transactions since 2016).
The overall number of M&A deals in 2016 increased by 1% compared to the year before (Thomson Reuters), but this fact did not grab headlines because the dollar value of M&A deals fell by 16%, mostly due to a significant drop in blockbuster deals. Tech was the second busiest M&A industry in 2016 behind energy.
We organize all of the trending information in your field so you don't have to. Join 38,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content